Study finds new ideas for leukemia treatment

Share This Post

A new study from McMaster University in Canada said that it has discovered a new treatment strategy for acute myeloid leukemia. By stimulating the production of fat cells in the bone marrow and adjusting the bone marrow microenvironment, it can inhibit leukemia cells and stimulate normal blood cell production. This difference is The indirect treatment strategy of the current standard treatment seems to have advantages, not only the outside but also the inside. (Nat Cell Biol. 2017; 19: 1336-1347. Doi: 10.1038 / ncb3625.)

Acute myeloid leukemia (AML) is characterized by the generation of heterogeneous leukemia cells. Patients suffer from severe infection and anemia due to insufficient production of normal red blood cells. Conventional standard treatment is focused on killing leukemia cells with firepower, ignoring the production of healthy red blood cells.

Based on the observation of leukemia patients, the researchers collected a large number of bone marrow samples from leukemia patients for research, compared and imaged healthy cells in the bone marrow and leukemia cells, and discovered this effect of fat cells. Through in vitro cell culture and transplantation tumor model experiments, the researchers found that acute myeloid leukemia cells specifically destroyed the  microenvironment of fat cells in the bone marrow, resulting in an unbalanced regulation of hematopoietic stem cells and progenitor cells and curbing the production of normal blood cells in the bone marrow.

The study revealed for the first time this relationship between the generation of adipocytes in the bone marrow and normal bone marrow erythrocytes. This effect is not only due to the hematopoietic microenvironment of the bone marrow, that is, the niche is crowded, but also the role of adipocytes in the differentiation process. The limiting effect of leukemia cells. This discovery provides new treatment ideas for myeloid leukemia and is expected to improve the symptoms of failure in patients with myeloid leukemia.

Supported by a drug that promotes the production of fat cells, the fat cells in the bone marrow successfully squeezed away the leukemia cells, making room for healthy blood cell production and clearing the portal. In vitro experiments, PPARγ inhibitors can induce the generation of bone marrow adipocytes. By changing the bone marrow microenvironment, it provides vitality for healthy blood cell production and at the same time inhibits the formation of leukemia cells, which may provide a new way of indirect treatment for acute myeloid leukemia. This indirect treatment strategy should be more promising than standard treatments, which have not made much progress over the past few decades.

The researchers pointed out that the focus of the existing standard treatment is to kill tumor cells, change the way of thinking, and adopt different strategies to change the survival environment of cancer cells to achieve therapeutic effects. While suppressing cancer cells, it strengthens healthy cells so that they can regenerate in a new environment induced by drugs. 

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Gamma Delta T Cell therapy in Malaysia
CAR T-Cell therapy

Gamma Delta T Cell Therapy in Malaysia: A Revolution in Cancer Treatment

Gamma Delta T Cell therapy is revolutionizing cancer treatment by harnessing the immune system’s power. This innovative approach is gaining momentum in Malaysia, a rising medical hub in Southeast Asia. With cutting-edge facilities, cost-effective treatments, and strong government support, Malaysia is advancing this therapy to offer hope to cancer patients. By focusing on research and international collaborations, the country is poised to lead the region in next-generation cancer care.

Gamma Delta T Cell therapy in Sinagpore
CAR T-Cell therapy

Gamma Delta T Cell Therapy in Singapore: A Revolutionary Approach for Late-Stage Cancer Treatment

Gamma Delta (GD) T Cell therapy is revolutionizing stage 4 cancer treatment, offering hope to metastatic cancer patients. At Singapore’s National University Hospital (NUH), the ANGELICA trials harness the unique tumor-targeting abilities of GD T cells. This cutting-edge therapy minimizes side effects, enhances survival rates, and improves quality of life. As a global leader in medical innovation, Singapore positions itself as a premier destination for advanced cancer therapies like GD T Cell therapy.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy